Pulse therapy and its modifications in pemphigus: a six year study.

Area of Science:

• Dermatology
• Immunodermatology
• Autoimmune Blistering Diseases

Background:

• Dexamethasone-cyclophosphamide pulse (DCP) therapy is a common treatment for pemphigus in India.
• Cyclophosphamide in DCP therapy is associated with significant adverse effects.
• Limitations of standard DCP therapy necessitate exploring alternative treatment protocols.

Purpose of the Study:

• To evaluate the efficacy and utility of modified pulse therapy for pemphigus.
• To assess treatment outcomes with modifications to the original DCP protocol.
• To explore the potential of azathioprine or methotrexate as cyclophosphamide alternatives.

Main Methods:

• A cohort of 41 pemphigus patients received modified pulse therapy between 1995 and 2001.
• Modifications included protocol adjustments and cyclophosphamide substitution with azathioprine or methotrexate in select cases.
• Treatment adherence and response were monitored.

Main Results:

• A good therapeutic response was observed in 34 patients who consistently followed the treatment regimen.
• The modified pulse therapy demonstrated clinical effectiveness in managing pemphigus.
• No specific mention of side effect profile in the results section.

Conclusions:

• Modifications to the standard Dexamethasone-cyclophosphamide pulse (DCP) therapy protocol are highly effective.
• The adapted pulse therapy approach offers a beneficial and useful treatment strategy for pemphigus patients.
• This study supports the clinical utility of modified pulse therapy in pemphigus management.